EUVIMEDEUVIMED entdecken
Crossref

FGL1 Drives Epithelial–Mesenchymal Transition and Cisplatin Resistance in Laryngeal Squamous Cell Carcinoma

Shuang Teng iD, Meng Jin, Bing-Rui Yan, Ling-Mei Qu, Zhao-Nan Xu, Shuo Liu iD, Qiu-Ying Li, Feng-Shuo Zhang, Qing Hao, Shuang Guo, Rui Zhao iD, Ya-Nan Sun iD

Head & Neck · 15.11.2026

DOI: 10.1002/hed.70545 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, online erschienen am 15.11.2026. Verfasst von Shuang Teng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Head and Neck Surgery, Second Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang, China. Die Arbeit nennt 20 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Wuyuan Research Fund of the Fifth Affiliated Hospital of Harbin Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fibrinogen‐like protein 1 (FGL1) is involved in tumor progression and immune regulation, but its role in laryngeal squamous cell carcinoma (LSCC) is unclear.

Methods

Plasma FGL1 levels were measured in 120 LSCC patients and 50 controls using ELISA. Tissue expression was analyzed via TCGA‐HNSC. Functional assays evaluated proliferation, migration, invasion, apoptosis, and cisplatin sensitivity. Prognostic value was assessed using survival and regression analyses.

Results

FGL1 was significantly elevated in LSCC plasma and tumor tissues. Functional studies showed that FGL1 promotes proliferation, migration, invasion, and EMT while inhibiting apoptosis and enhancing cisplatin resistance. Mechanistically, FGL1 knockdown increased Cleaved Caspase‐3 and decreased Bcl‐2 expression. High FGL1 levels were associated with poorer overall survival and independently predicted prognosis.

Conclusion

FGL1 promotes LSCC progression and chemoresistance, highlighting its potential as a circulating biomarker and therapeutic target.

Schlagwörter

Stichwörter der Autor:innen

EMTFGL1LSCCapoptosisbiomarkerprognosis

Autor:innen und Institutionen

  • Department of Otolaryngology, Head and Neck Surgery, Second Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang, China.
  • Department of Otolaryngology, Head and Neck Surgery, Fifth Affiliated Hospital, Harbin Medical University, Daqing, Heilongjiang, China.

ORCID-Profile: Shuang Teng, Shuo Liu, Rui Zhao, Ya-Nan Sun

Förderung

  • National Natural Science Foundation of China
  • Wuyuan Research Fund of the Fifth Affiliated Hospital of Harbin Medical University

Zitieren

APA

Teng, S., Jin, M., Yan, B. R., Qu, L. M., Xu, Z. N., Liu, S., Li, Q. Y., Zhang, F. S., Hao, Q., Guo, S., Zhao, R., & Sun, Y. N. (2026). FGL1 Drives Epithelial–Mesenchymal Transition and Cisplatin Resistance in Laryngeal Squamous Cell Carcinoma. Head & Neck. https://doi.org/10.1002/hed.70545

Vancouver

Teng S, Jin M, Yan BR, Qu LM, Xu ZN, Liu S, et al. FGL1 Drives Epithelial–Mesenchymal Transition and Cisplatin Resistance in Laryngeal Squamous Cell Carcinoma. Head & Neck. 2026. doi:10.1002/hed.70545

BibTeX
@article{Teng2026,
  author = {Teng, Shuang and Jin, Meng and Yan, Bing-Rui and Qu, Ling-Mei and Xu, Zhao-Nan and Liu, Shuo and Li, Qiu-Ying and Zhang, Feng-Shuo and Hao, Qing and Guo, Shuang and Zhao, Rui and Sun, Ya-Nan},
  title = {FGL1 Drives Epithelial–Mesenchymal Transition and Cisplatin Resistance in Laryngeal Squamous Cell Carcinoma},
  journal = {Head & Neck},
  year = {2026},
  doi = {10.1002/hed.70545}
}
Kostenlos starten →